 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Victory Capital Management Inc. decreased its stake in BioSpecifics Technologies
  Corp. (NASDAQ:BSTC) by 3.0% in the third quarter, according to the company in its
  most recent filing with the Securities  Exchange Commission. The institutional investor
  owned 4,181 shares of the biopharmaceutical ...


BioSpecifics Technologies Corp. (NASDAQ:BSTC) Holdings Cut by Victory Capital Management Inc.

---
- California Public Employees Retirement System lifted its position in BioSpecifics
  Technologies Corp. (NASDAQ:BSTC) by 2.9% during the third quarter, according to
  its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
  The fund owned 14,252 shares of the biopharmaceutical ...


California Public Employees Retirement System Boosts Stock Position in BioSpecifics Technologies Corp. (NASDAQ:BSTC)

---
- Acadian Asset Management LLC decreased its holdings in BioSpecifics Technologies
  Corp. (NASDAQ:BSTC) by 98.2% during the 3rd quarter, according to the company in
  its most recent filing with the SEC. The fund owned 739 shares of the biopharmaceutical
  companys stock after selling 41,290 shares ...


Acadian Asset Management LLC Sells 41,290 Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC)

---
- BioSpecifics Technologies Corp. (NASDAQ:BSTC) was the target of a large growth in
  short interest during the month of November. As of November 15th, there was short
  interest totalling 74,100 shares, a growth of 22.5% from the October 31st total
  of 60,500 shares. Based on an average daily volume of ...


BioSpecifics Technologies Corp. (NASDAQ:BSTC) Sees Large Growth in Short Interest

---
- BioSpecifics Technologies Corp. (NASDAQ:BSTC) was the recipient of a significant
  increase in short interest in November. As of November 15th, there was short interest
  totalling 74,100 shares, an increase of 22.5% from the October 31st total of 60,500
  shares. Approximately 1.3% of the companys stock ...


Short Interest in BioSpecifics Technologies Corp. (NASDAQ:BSTC) Rises By 22.5%

---
- New York State Common Retirement Fund cut its stake in shares of BioSpecifics Technologies
  Corp. (NASDAQ:BSTC) by 12.0% during the third quarter, according to the company
  in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
  The firm owned 6,600 shares of the ...


New York State Common Retirement Fund Decreases Position in BioSpecifics Technologies Corp. (NASDAQ:BSTC)

---
- 'Endo International said Wednesday it has completed its previously announced $540
  million acquisition of BioSpecifics Technologies Corp., a Wilmington biopharmaceutical
  company. Under the terms of the agreement, Endo (NASDAQ: ENDP), which is based in
  Dublin, Ireland, and has its U.S. headquarters in Malvern, paid $88.50 per share
  to BioSpecifics shareholders in the all-cash transaction.'


Endo completes $540 million acquisition of BioSpecifics

---
- Wells Fargo  Company MN grew its stake in shares of BioSpecifics Technologies Corp.
  (NASDAQ:BSTC) by 14.8% in the third quarter, HoldingsChannel.com reports. The firm
  owned 138,508 shares of the biopharmaceutical companys stock after buying an additional
  17,835 shares during the quarter...


Wells Fargo & Company MN Grows Position in BioSpecifics Technologies Corp. (NASDAQ:BSTC)

---
- Royce  Associates LP cut its stake in BioSpecifics Technologies Corp. (NASDAQ:BSTC)
  by 1.7% during the third quarter, according to its most recent 13F filing with the
  Securities and Exchange Commission. The firm owned 132,058 shares of the biopharmaceutical
  companys stock after selling ...


Royce & Associates LP Cuts Position in BioSpecifics Technologies Corp. (NASDAQ:BSTC)

---
- BNP Paribas Arbitrage SA grew its position in shares of BioSpecifics Technologies
  Corp. (NASDAQ:BSTC) by 388.0% during the 3rd quarter, according to its most recent
  13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,464
  shares of the biopharmaceutical companys ...


BNP Paribas Arbitrage SA Increases Holdings in BioSpecifics Technologies Corp. (NASDAQ:BSTC)

BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren’s contracture and Peyronie’s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Market Cap	$650.25M
52-Wk High	$89.15
52-Wk Low	$42.00

Current Price	$0.00
Prev Close	$88.53
Open	$0.00
Dividend Yield	N/A
50-Day Moving Average	$76.94
Beta	0.76
Avg. Volume	115,309.80
PE Ratio	37.55

52-Week High	$89.15
52-Week Low	$42.00
Market Capitalization	$650.25M
EPS	N/A
Price to Book	4.81
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

BSTC BioSpecifics Technologies Corp.

About

Feed

News

Fundamentals